CNBX Pharmaceuticals (CNBX) Enterprise Value (2016 - 2025)
CNBX Pharmaceuticals (CNBX) has disclosed Enterprise Value for 13 consecutive years, with -$7703.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 55.57% year-over-year to -$7703.0, compared with a TTM value of -$7703.0 through Nov 2025, up 55.57%, and an annual FY2025 reading of -$15111.0, up 42.8% over the prior year.
- Enterprise Value was -$7703.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$15111.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$7703.0 in Q4 2025 and bottomed at -$2.0 million in Q2 2021.
- Average Enterprise Value over 5 years is -$324114.8, with a median of -$60577.0 recorded in 2023.
- The sharpest move saw Enterprise Value tumbled 327.33% in 2021, then skyrocketed 97.25% in 2022.
- Year by year, Enterprise Value stood at -$786414.0 in 2021, then surged by 97.25% to -$21600.0 in 2022, then plummeted by 278.0% to -$81647.0 in 2023, then soared by 78.76% to -$17339.0 in 2024, then soared by 55.57% to -$7703.0 in 2025.
- Business Quant data shows Enterprise Value for CNBX at -$7703.0 in Q4 2025, -$15111.0 in Q3 2025, and -$13648.0 in Q2 2025.